Recent Updates
Recently added Catalysts
AVXL

Filed by newsfilecorp.com

Key Takeaway: ANAVEX LIFE SCIENCES CORP. CONSOLIDATED BALANCE SHEETS September 15, 2015 and September 30, September 15, September 30, 2015 2014 Current Cash $ 13,101,846 $ 7,262,138 Prepaid expenses 79,321 89,117 Total current assets 13,181,167 7,351,255 Equipment

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+57%
120-day peak, hindsight
Typical move
10.3%
average across 4 past catalysts
Cash runway
~49 mo
Minimal dilution risk
Lead asset
ANAVEX2-73
Phase 3 · Rett Syndrome

Full Press Release Details

ANAVEX LIFE SCIENCES CORP.
CONSOLIDATED BALANCE SHEETS
September 15, 2015 and September 30,
September 15, September 30,
2015 2014
Current
Cash $ 13,101,846 $ 7,262,138
Prepaid expenses 79,321 89,117
Total current assets 13,181,167 7,351,255
Equipment 1,501 2,247
Total assets $ 13,182,668 $ 7,353,502
Current
Accounts payable and accrued liabilities $ 1,016,369 $ 1,249,084
Promissory notes payable 92,516 192,065
Total current liabilities 1,108,885 1,441,149
Non-interest bearing liabilities 436 5,719,727
Total liabilities 1,109,321 7,160,876
STOCKHOLDERS' EQUITY
Capital stock
Authorized:
400,000,000 common shares, par value $0.001 per share
Issued and outstanding:
124,503,297 common shares (September 30, 2014 - 47,200,237) 124,503 47,201
Additional paid-in capital 72,949,380 52,078,750
Common stock to be issued 777,415 640,000
Accumulated deficit (61,777,951 ) (52,573,325 )
Total stockholders' equity 12,073,347 192,626
Total liabilities and stockholders' equity $ 13,182,668 $ 7,353,502
Last updated: Sep 15, 2015